IMF Videos Search Content For Healthcare Professional (132) Healthcare Provider (132) Care Partner (67) Patient (67) Series - Any - ASCO/EHA (51) ASH (69) Ask Dr. Durie (23) Black Swan Research Initiative (2) Emerging Therapies (3) Facebook Live (6) IMWG (4) Living Well with Myeloma (2) Myeloma in a Minute (5) Myeloma Made Simple (5) Myeloma University (4) Patient & Family Webinar (1) Q&A (11) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (68) High-Risk Myeloma (45) High-risk Smoldering Myeloma (38) Late Relapse (4–6 Lines of Therapy) (84) MGUS (39) Newly Diagnosed (Pre-Treatment or First Treatment) (63) Smoldering Myeloma (49) Types of Therapy Immunomodulatory drugs (IMiDs) (60) Immunotherapies (CAR T; BiTE, etc.) (100) Monoclonal antibodies (54) Proteasome inhibitors (46) Stem cell transplant (38) Steroids (42) Supportive Care (43) Year Published 2026 (20) 2025 (32) 2024 (52) 2023 (43) 2022 (17) 2021 (12) 2020 (1) 2019 (10) 2018 (2) 2017 (1) 2016 (2) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (20) Dr. María-Victoria Mateos (7) Dr. Saad Usmani (3) Dr. Shaji Kumar (2) Dr. Sigurður Kristinsson (2) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (1) Donna Catamero, ANP-BC, OCN, CCRC (1) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Once Weekly Selinexor, Carfilzomib and Dexamethasone in Triple Class Refractory Multiple Myeloma January 10, 2023 ASH MGUS and Risk of Chronic Kidney Disease: Results of the Population-Based iStopMM Study January 2, 2023 ASH Circulating Tumor Plasma Cells in the Screened iStopMM Smoldering Multiple Myeloma Cohort January 2, 2023 ASH Clinical Impact of NGF in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess MRD in Newly Diagnosed Multiple Myeloma Pts Receiving Maintenance December 27, 2022 ASH Ultra-Sensitive Assessment of MRD in Peripheral Blood of Multiple Myeloma Patients Using Bloodflow December 26, 2022 ASH Autoimmune Diseases Are Not Associated with MGUS: Results of the Population-Based iStopMM December 23, 2022 ASH Hypercalcemia in Individuals with MGUS: Results from the iStopMM Study December 23, 2022 ASH Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T-cell Therapy December 23, 2022 ASH Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma: Post-Hoc Analysis of Sustained Undetectable MRD December 22, 2022 ASH Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: iStopMM Study December 21, 2022 ASH The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma December 21, 2022 ASH Does SARS-CoV-2 Vaccination Impact the Risk of Progression from MGUS to MM? December 16, 2022 ASH Load More
